BioNTech SE Share Price Wiener Boerse

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

End-of-day quote Wiener Boerse 23:00:00 16/06/2024 BST 5-day change 1st Jan Change
82.7 EUR -5.27% Intraday chart for BioNTech SE -5.27% -13.39%

Financials

Sales 2024 * 2.75B 2.93B 232B Sales 2025 * 2.74B 2.93B 232B Capitalization 19.12B 20.44B 1,617B
Net income 2024 * -419M -448M -35.44B Net income 2025 * -548M -586M -46.35B EV / Sales 2024 * 2.35 x
Net cash position 2024 * 12.67B 13.55B 1,072B Net cash position 2025 * 12.02B 12.85B 1,017B EV / Sales 2025 * 2.59 x
P/E ratio 2024 *
-43.8 x
P/E ratio 2025 *
-34.7 x
Employees 6,133
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.48%
More Fundamentals * Assessed data
Dynamic Chart
US FDA Places Partial Clinical Hold on BioNTech's Cancer Drug Trial MT
Sector Update: Health Care Stocks Ease in Afternoon Trading MT
Top Midday Stories: Nvidia Gets SCOTUS Review of Crypto Sales Lawsuit; Apple Supplier Develops Material for Solid-State Batteries; OpenAI Reportedly Launches Medical AI Tool; Walt Disney's 'Inside Out 2' Sets Biggest Opening of 2024; IQVentures to Acquire Aaron's MT
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading MT
BioNTech Says US FDA Placed Partial Clinical Hold on Cancer Drug Trial MT
US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug RE
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading MT
Indonesia ramps up fight against tuberculosis amid concerns on economic impact RE
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say RE
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading MT
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab CI
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower MT
BioNTech, CEPI Expand Partnership for mRNA Vaccine Ecosystem in Africa MT
More news
1 day-5.27%
1 week-5.27%
Current month-10.16%
1 month-1.78%
3 months-3.25%
6 months-12.62%
Current year-13.39%
More quotes
1 week
78.75
Extreme 78.75
87.20
1 month
78.75
Extreme 78.75
95.30
Current year
78.75
Extreme 78.75
103.00
1 year
78.75
Extreme 78.75
115.25
3 years
78.75
Extreme 78.75
394.10
5 years
65.89
Extreme 65.89
394.10
10 years
65.89
Extreme 65.89
394.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 01/06/08
Founder 57 01/06/08
Director of Finance/CFO 60 30/06/21
Members of the board TitleAgeSince
Director/Board Member 70 31/12/21
Director/Board Member 67 01/06/08
Chairman 53 01/06/08
More insiders
Date Price Change Volume
21/06/24 78.75 -2.11% 0
20/06/24 80.45 +0.31% 0
19/06/24 80.2 -1.35% 4
18/06/24 81.3 -1.69% 0
17/06/24 82.7 -5.27% 10

End-of-day quote Wiener Boerse, June 16, 2024

More quotes
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
79.22 EUR
Average target price
103.5 EUR
Spread / Average Target
+30.61%
Consensus